Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Authors:
- Florian LordickFLFlorian Lordick
- Yoon-Koo KangYKYoon-Koo Kang
- Hyun-Cheol ChungHCHyun-Cheol Chung
- Pamela SalmanPSPamela Salman
- Sang Cheul OhSOSang Cheul Oh
- György BodokyGBGyörgy Bodoky
- Galina KurtevaGKGalina Kurteva
- Constantin VolovatCVConstantin Volovat
- Vladimir M MoiseyenkoVMVladimir M Moiseyenko
- Vera GorbunovaVGVera Gorbunova
- Joon Oh ParkJPJoon Oh Park
- Akira SawakiASAkira Sawaki
Top Cited Papers
- 1 May 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (6) , 490-499
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialThe Lancet Oncology, 2013
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)British Journal of Cancer, 2010
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)British Journal of Cancer, 2009
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancerBritish Journal of Cancer, 2009
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001